Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 214

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 1B
Chunk 214
---
     
    Commercial License and Option Agreement between Registrant and Wisconsin Alumni Research Foundation (“WARF Agreement”)
     
    10.1
     
    8-K
     
    January 9, 2008
     
    001-12830

    10.09(a)
     
    First Amendment to WARF Agreement dated March 11, 2009
     
    10.38
     
    10-K
     
    March 23, 2009
     
    001-12830

    10.10**
     
    Second Amended and Restated License Agreement dated June 15, 2017, between Cell Cure Neurosciences, Ltd. and Hadasit Medical Research Services and Development Ltd. (“Hadasit License”)
     
    10.1
     
    10-Q
     
    August 8, 2024
     
    001-12830

    10.10(a)
     
    Amendment to Hadasit License dated January 8, 2018
     
    10.38
     
    10-K
     
    March 15, 2018
     
    001-12830

    10.10(b)††
     
    Second Amendment to Hadasit License dated December 1, 2019
     
    10.4(b)
     
    10-K
     
    March 10, 2022
     
    001-12830

137

    10.10(c)††
     
    Side Letter Agreement dated December 17, 2021 between Hadasit Medical Research Services and Development Ltd., Cell Cure Neurosciences Ltd., Genentech, Inc. and F. Hoffmann-La Roche Ltd
     
    10.4(c)
     
    10-K
     
    March 10, 2022
     
    001-12830

    10.10(d)††
     
    Second Side Letter Agreement dated December 17, 2021 between Hadasit Medical Research Services and Development Ltd. and Cell Cure Neurosciences Ltd.
     
    10.4(d) 
     
    10-K
     
    March 10, 2022
     
    001-12830

    10.11†
     
    Debt and Note Purchase Agreement dated June 16, 2017, as amended June 29